KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC

被引：54
|
作者：
Cortes, J. [1 ,2 ,3 ,4 ]
Cescon, D. W. [5 ]
Rugo, H. S. [6 ]
Im, S-A. [7 ]
Yusof, M. Md [8 ]
Gallardo, C. [9 ]
Lipatov, O. [10 ]
Barrios, C. H. [11 ]
Perez-Garcia, J. [1 ]
Iwata, H. [12 ]
Masuda, N. [13 ]
Otero, M. Torregroza [14 ]
Gokmen, E. [15 ]
Loi, S. [16 ,17 ]
Guo, Z. [18 ]
Zhou, X. [18 ]
Karantza, V. [18 ]
Pan, W. [18 ]
Schmid, P. [19 ]
机构：
[1] Int Breast Canc Ctr IBCC, Quiron Grp, Madrid, Spain
[2] Int Breast Canc Ctr IBCC, Quiron Grp, Barcelona, Spain
[3] Vall dHebron Inst Oncol, Barcelona, Spain
[4] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Hematol Oncol, San Francisco, CA 94143 USA
[7] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[8] Pantai Hosp, Ctr Canc, Kuala Lumpur, Malaysia
[9] Arturo Lopez Perez Fdn, Inst Oncol, Santiago, Chile
[10] Republican Clin Oncol Dispensary, Dept Oncol, Republic Bashkortostan, Russia
[11] Pontificia Univ Catolica Rio Grande do Sul, Oncol Res Unit, Hosp Sao Lucas, Porto Alegre, RS, Brazil
[12] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan
[13] Natl Hosp Org Osaka Natl Hosp, Breast Oncol, Dept Surg, Osaka, Japan
[14] Oncomedica SA, Hematol & Oncol, Monteria, Colombia
[15] Ege Univ, Fac Med, Sch Med, Izmir, Turkey
[16] Peter MacCallum Canc Ctr, Div Canc Res, Melbourne, Vic, Australia
[17] Univ Melbourne, Sir Peter MacCallum Dept Med Oncol, Parkville, Vic, Australia
[18] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ USA
[19] Ctr Expt Canc Med, Barts Canc Inst, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页码：S1289 / S1290
页数：2
相关论文
共 50 条
  • [21] Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer
    Rugo, Hope
    Schmid, Peter
    Nowecki, Zbigniew
    Cescon, David
    Im, Seock-Ah
    Yusof, Mastura
    Gallardo, Carlos
    Iwata, Hiroji
    Barrios, Carlos
    Loi, Sherene
    Zhou, Xuan
    Zhang, Xiaoli
    Pan, Wilbur
    Karantza, Vassiliki
    Cortes, Javier
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
    Cescon, David W.
    Schmid, Peter
    Rugo, Hope S.
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos H.
    Perez-Garcia, Jose
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Haiderali, Amin
    Zhou, Xuan
    Guo, Zifang
    Nguyen, Allison Martin
    Cortes, Javier
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (05): : 717 - 727
  • [23] KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
    Gandhi, Leena
    Rodgriguez-Abreu, Delvys
    Gadgeel, Shirish
    Esteban, Emilio
    Felip, Enriqueta
    De Angelis, Flavia
    Domine, Manuel
    Clingan, Philip
    Hochmair, Maximilian J.
    Powell, Steven
    Cheng, Susanna Yee-Shan
    Bischoff, Helge G.
    Peled, Nir
    Grossi, Francesco
    Jennens, Ross R.
    Reck, Martin
    Hui, Rina
    Garon, Edward B.
    Boyer, Michael
    Rubio-Viqueira, Belen
    Novello, Silvia
    Kurata, Takayasu
    Gray, Jhanelle E.
    Vida, John J.
    Wei, Ziwen
    Yang, Jing
    Raftopoulos, Harry
    Pietanza, M. Catherine
    Garassino, Marina C.
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia
    Yusof, M. Md
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Holgado, E.
    Iwata, H.
    Masuda, N.
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Jensen, E.
    Aktan, G.
    Karantza, V.
    Schmid, P.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1257 - S1257
  • [25] Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355
    Hattori, Masaya
    Masuda, Norikazu
    Takano, Toshimi
    Tsugawa, Koichiro
    Inoue, Kenichi
    Matsumoto, Koji
    Ishikawa, Takashi
    Itoh, Mitsuya
    Yasojima, Hiroyuki
    Tanabe, Yuko
    Yamamoto, Keiko
    Suzuki, Masato
    Pan, Wilbur
    Cortes, Javier
    Iwata, Hiroji
    CANCER MEDICINE, 2023, 12 (09): : 10280 - 10293
  • [26] Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
    Schmid, P.
    Cortes, J.
    Dent, R. A.
    Pusztai, L.
    McArthur, H. L.
    Kummel, S.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Foukakis, T.
    Reynier, M. A. Mouret
    Ferreira, M. I. R.
    Im, S. A.
    Cardoso, F.
    Ding, Y.
    Pan, W.
    Tryfonidis, K. E.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1257 - S1257
  • [27] KEYNOTE-590: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer
    Kato, Ken
    Shah, Manish
    Enzinger, Peter
    Bennouna, Jaafar
    Shen, Lin
    Adenis, Antoine
    Zhu, Ying
    Bhagia, Pooja
    Koshiji, Minori
    Doi, Toshihiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [28] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
    Di Leo, Angelo
    Gomez, Henry L.
    Aziz, Zeba
    Zvirbule, Zanete
    Bines, Jose
    Arbushites, Michael C.
    Guerrera, Stephanie F.
    Koehler, Maria
    Oliva, Cristina
    Stein, Steven H.
    Williams, Lisa S.
    Dering, Judy
    Finn, Richard S.
    Press, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5544 - 5552
  • [29] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    Tabernero, J.
    Bang, Y.
    Van Cutsem, E.
    Fuchs, C.
    Janjigian, Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Qin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
  • [30] Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
    Galsky, Matthew D.
    Mortazavi, Amir
    Milowsky, Matthew, I
    George, Saby
    Gupta, Sumati
    Fleming, Mark T.
    Dang, Long H.
    Geynisman, Daniel M.
    Walling, Radhika
    Alter, Robert S.
    Kassar, Mohamad
    Wang, Jue
    Gupta, Shilpa
    Davis, Nancy
    Picus, Joel
    Philips, George
    Quinn, David, I
    Haines, G. Kenneth, III
    Hahn, Noah M.
    Zhao, Qianqian
    Yu, Menggang
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1797 - +
12345